You just read:

Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Apr 01, 2019, 07:30 ET